News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
PDD Holdings (NASDAQ: PDD) saw its shares drop 7.6% last week, underperforming competitors and the broader China internet ETF, largely due to concerns over upcoming July retail data in China. Despite having substantial cash reserves ($63.2 billion), which represent 53% of its estimated equity …
RBC Capital analyst Matthew Hedberg maintained a Hold rating on PagerDuty (PD) with a $12.00 price target. The company recently reported quarterly revenue of $120.97 million and a net profit of $5.28 million. Insider sentiment for PD is negative, with recent significant share sales …
Himalaya Capital Management LLC has significantly increased its stake in PDD Holdings (PDD) by adding 6,153,119 shares to its portfolio. This substantial acquisition reflects a strong vote of confidence in the e-commerce giant's future performance. The fund's updated holdings indicate a strategic investment in …
RBC Capital has maintained its 'Sector Perform' rating for PagerDuty (PD) and increased the price target from $9.00 to $12.00, signaling potential growth despite mixed analyst opinions. GuruFocus identifies PagerDuty as 45.4% undervalued with a GF Value™ of $21.82, yet insider selling and lower …
PDS Biotechnology Corporation shareholders have approved an amendment to the company's certificate of incorporation, increasing the number of authorized common shares from 150 million to 300 million. They also elected two Class B directors, Kamil Ali-Jackson and Ilian Iliev, and ratified KPMG US LLP …
PDS Biotechnology Corporation announced that its stockholders approved an amendment to increase the authorized common stock from 150,000,000 to 300,000,000 shares. Additionally, stockholders elected Kamil Ali-Jackson, J.D. and Ilian Iliev, Ph.D. as Class B directors to serve until the 2029 annual meeting. The meeting …
This article details Yarbrough Capital, LLC's historical holdings in PDD Holdings Inc (PDD). As of June 30, 2026, Yarbrough Capital held no shares, having made four purchases and three sales since their initial trade in Q4 2022, resulting in an estimated loss of $1.01 …
PagerDuty, Inc. (NYSE:PD) announced it will release its financial results for the second quarter fiscal year 2027 on August 27, 2026, after market close. The company will host an audio call for analysts and investors at 2:00 p.m. Pacific Time on the same day …
PDD Holdings Inc (PDD) shares recently dropped 5.5% to $84.17, leading GuruFocus to assess it as 46.5% undervalued with a GF Value™ estimate of $157.39. Despite a strong financial strength rating of 10/10 and high growth potential, its valuation and momentum ranks are lower, …
PDS Biotechnology reported a net loss of $17.1 million for the six months ended June 30, 2026, with cash and cash equivalents significantly reduced to $5.6 million from $26.7 million at year-end 2025. The company's management disclosed substantial doubt about its ability to continue …
PDD Holdings Inc (PDD) stock dropped by 4.79% on August 13th due to heightened investor caution regarding regulatory challenges and evolving trade policies affecting its international platform, Temu. The company faces pressure from emerging policy adjustments, compliance scrutiny, and heavy reinvestment in subsidies and …
PDS Biotechnology reported a net loss of $9.8 million for Q2 2026 and had $5.6 million in cash at quarter-end. The company announced a strategic refocus to prioritize its tumor-targeted IL-12 program, PDS0301, and will discontinue internal investment in PDS0101, seeking external partnerships for …
PDS Biotechnology Corporation announced its financial results for the second quarter ended June 30, 2026, reporting a net loss of $9.8 million. The company also provided a clinical and corporate update, highlighting positive clinical data for PDS0301 in metastatic colorectal cancer and announcing a …
Wasatch Advisors LP has made a new investment in PDD Holdings Inc. Sponsored ADR (NASDAQ:PDD), purchasing 47,950 shares valued at approximately $3.66 million in the second quarter. This move comes as institutional investors and hedge funds collectively own 39.83% of the company, despite PDD …
Shuo Zhang, a director at PDF Solutions Inc. (NASDAQ:PDFS), sold 1,501 shares of the company's common stock for $77,256. This transaction occurred after PDFS shares surged 158% over the past year, with the stock currently deemed overvalued by InvestingPro analysis. The sale follows recent …
This article reports on a Form 144 SEC filing by PDF Solutions Inc. (PDFS) on August 12, 2026. The filing indicates a proposed sale of 1501 shares of common stock with an aggregate market value of $77,257.22, acquired through restricted stock on August 1, …
Sanford C. Bernstein has upgraded PDF Solutions (NASDAQ:PDFS) to a "strong-buy" rating, while the broader analyst consensus remains a "Moderate Buy" with a target price of $58.50. The company recently reported quarterly EPS of $0.27, matching estimates, and revenue of $61.53 million, slightly exceeding …
Handelsbanken Fonder AB increased its stake in PDD Holdings Inc. (NASDAQ:PDD) by 9.1% in Q2, acquiring an additional 34,750 shares to bring its total to 415,029 shares valued at $31.7 million. This increase occurred despite PDD's recent quarterly earnings missing analyst expectations, with EPS …
Pdf Solutions Inc. (NASDAQ: PDFS) is showing weak near and mid-term sentiment despite a positive long-term outlook. The analysis highlights an exceptional short setup with a 56.9:1 risk-reward ratio, targeting a 16.6% downside. Three AI-generated trading strategies (Position, Momentum Breakout, and Risk Hedging) are …
This article provides an AI-generated analysis of Pagerduty Inc. (NYSE: PD), highlighting strong near and mid-term sentiment but a weak long-term outlook. It presents three distinct institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis emphasizes the …
Dimensional Fund Advisors LP has acquired a new stake in PagerDuty, purchasing 978,159 shares valued at approximately $6.07 million, representing about 1.15% of the company. PagerDuty's stock has a "Hold" consensus rating from analysts, with an average price target of $11.50, and recently exceeded …
PDS Biotechnology has announced the halt of its PDS0101 trial and internal investment, including the discontinuation of the Phase 3 VERSATILE-003 trial, to pivot its resources towards PDS0301. PDS0301, a tumor-targeted IL-12 immunocytokine, will now be the company's lead asset with a priority indication …
PDF Solutions (PDFS) has received an "Outperform" rating from Bernstein, with a price target of $65.00, signaling a positive outlook for the company. Despite this, GuruFocus indicates PDFS is 17.3% overvalued with a GF Value of $41.76, and its GF Score of 65/100 points …
PDS Biotechnology Corporation's stock crashed by approximately 67% after the company announced a strategic refocus of its resources towards the PDS0301 program for metastatic colorectal cancer. This shift is based on encouraging clinical data and a belief that PDS0301 offers a more attractive path …
PDF Solutions (PDFS) saw its stock rise by 7.3% after reaffirming its 20% annual revenue growth target for 2026 and reporting strong Q2 results. The company also filed a US$91.80 million shelf registration for common shares related to an employee stock ownership plan, highlighting …
PDS Biotech has scheduled the release of its quarterly financial results for the quarter ending June 30, 2026, on August 13, 2026. This announcement was initially published by PDS Biotechnology Corporation via GlobeNewswire. The news brief was created by Public Technologies (PUBT) using generative …
This article announces the filing of a Form 8K by PDS Biotechnology Corp for August 11, as reported by Investing.com. It provides a brief update on company filings without further details on the content of the Form 8K. The article appears to be a …
PDS Biotechnology (Nasdaq: PDSB) announced a strategic refocus, prioritizing its tumor-targeted IL-12 immunocytokine PDS0301 and discontinuing internal investment in the PDS0101 Phase 3 VERSATILE-003 trial, instead seeking strategic partnerships for PDS0101. This decision follows promising Phase 2 data for PDS0301 in metastatic colorectal cancer …
Search by ticker symbol or company name and select a result to open its chart.